These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 32102477)

  • 1. MiRNA-Based Inspired Approach in Diagnosis of Prostate Cancer.
    Munteanu VC; Munteanu RA; Onaciu A; Berindan-Neagoe I; Petrut B; Coman I
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32102477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. American Urological Association (AUA) guideline on prostate cancer detection: process and rationale.
    Carter HB
    BJU Int; 2013 Sep; 112(5):543-7. PubMed ID: 23924423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The level of evidence for the use of biomarkers in the early detection of prostate cancer].
    Lamy PJ; Gauchez AS; Salomon L; Haugh M; Ceraline J; Fulla Y; Georges A; Larré S; Loric S; Luporsi E; Martin PM; Mazerolles C; Molinié V; Mongiat-Artus P; Piffret J; Thuillier F; Perrin P; Rebillard X;
    Ann Biol Clin (Paris); 2016; 74(2):227-32. PubMed ID: 27029727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NCCN Guidelines Updates: Prostate Cancer and Prostate Cancer Early Detection.
    Carroll PH; Mohler JL
    J Natl Compr Canc Netw; 2018 May; 16(5S):620-623. PubMed ID: 29784740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early-stage prostate cancer, PSA screening rates decline.
    Printz C
    Cancer; 2016 Mar; 122(6):825. PubMed ID: 26938268
    [No Abstract]   [Full Text] [Related]  

  • 6. Navigating Prostate Cancer Screening in the Real World of Primary Care: The Mirage and the Quicksand.
    Mathew P; Hachem H; Han P
    JAMA Oncol; 2018 Apr; 4(4):453-454. PubMed ID: 29470576
    [No Abstract]   [Full Text] [Related]  

  • 7. [New challenges and earlier approved methods in the laboratory diagnosis of prostate cancer].
    Kovács GL
    Magy Onkol; 2014 Dec; 58(4):301-9. PubMed ID: 25517448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.
    Eapen RS; Herlemann A; Washington SL; Cooperberg MR
    Curr Opin Urol; 2017 May; 27(3):205-209. PubMed ID: 28221220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
    Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
    Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Prostate Specific Antigen (PSA), yet how much damage?].
    Braillon A; Hill C; Dubois G
    Presse Med; 2012 May; 41(5):482-5. PubMed ID: 22336482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. National trends in prostate cancer screening among older American men with limited 9-year life expectancies: evidence of an increased need for shared decision making.
    Drazer MW; Prasad SM; Huo D; Schonberg MA; Dale W; Szmulewitz RZ; Eggener SE
    Cancer; 2014 May; 120(10):1491-8. PubMed ID: 24523016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-Specific Antigen Testing Initiation and Shared Decision-Making: Findings from the 2000 and 2015 National Health Interview Surveys.
    Li J; Ding H; Richards TB; Martin I; Kobrin S; Marcus PM
    J Am Board Fam Med; 2018; 31(4):658-662. PubMed ID: 29986994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Landmarks in prostate cancer screening.
    Schröder FH
    BJU Int; 2012 Oct; 110 Suppl 1():3-7. PubMed ID: 23046034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Personalized Risks of Over Diagnosis for Screen Detected Prostate Cancer Incorporating Patient Comorbidities: Estimation and Communication.
    Gulati R; Psutka SP; Etzioni R
    J Urol; 2019 Nov; 202(5):936-943. PubMed ID: 31112106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reconsidering Prostate Cancer Screening.
    Schmidt C
    J Natl Cancer Inst; 2017 Jan; 109(1):1-2. PubMed ID: 28104781
    [No Abstract]   [Full Text] [Related]  

  • 16. National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
    Drazer MW; Huo D; Eggener SE
    J Clin Oncol; 2015 Aug; 33(22):2416-23. PubMed ID: 26056181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early detection of prostate cancer.
    Taneja SS
    Urol Clin North Am; 2014 May; 41(2):xi-xii. PubMed ID: 24725495
    [No Abstract]   [Full Text] [Related]  

  • 18. [Current results on PSA-based prostate cancer detection].
    Graefen M; Schlomm T; Steuber T; Sauter G
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):312-7. PubMed ID: 24562706
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PSA cancer screening: a case for shared decision-making.
    Dasarathy J; Rajesh R
    J Fam Pract; 2020; 69(1):26;28;30;32;46. PubMed ID: 32017831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostate-specific antigen, prostate cancer screening, and the pathologist: what should be our role?
    Jackson BR
    Arch Pathol Lab Med; 2013 Mar; 137(3):308-9. PubMed ID: 22799565
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.